Fluconazole transdermal

Drug Profile

Fluconazole transdermal

Alternative Names: Fluconazole transdermal patch - Watson Pharmaceuticals; Onychomycosis patch - Watson Pharmaceuticals

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Watson Pharmaceuticals
  • Class Antifungals; Azoles; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Onychomycosis

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 05 Feb 2004 Discontinued - Phase-III for Onychomycosis in USA (Transdermal)
  • 11 Dec 2003 Data from a media release have been added to the adverse events and Mycoses therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top